Literature DB >> 11424632

Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS).

S M Gold1, C Heesen, H Schulz, U Guder, A Mönch, J Gbadamosi, C Buhmann, K H Schulz.   

Abstract

Quality of life (QoL) is discussed as an additional outcome measure in multiple sclerosis (MS). However, few questionnaires assessing disease specific QoL in MS have been published. On the basis of the literature and interviews with clinicians and MS patients, we have developed a disease specific QoL instrument and validated it in a broad range of patients with MS. In this study, a heterogeneous sample of n = 237 MS patients completed the newly developed Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS, in German language) and a battery of already validated questionnaires. They further underwent neurological scoring and objective tests. By these means, we investigated its validity, appropriateness, internal consistency, and retest reliability. Internal consistency and retest coefficients were high and satisfied psychometric standards. Convergent and discriminant validity was supported by direction, magnitude and pattern of correlations with other health measures. HAQUAMS subscales and its total score distinguished between patient groups of varied disease severity, cognitive impairment, and affective symptomatology. No floor or ceiling effects were found in either of the HAQUAMS subscales. The HAQUAMS is a reliable, valid and appropriate instrument for QoL assessment in multiple sclerosis. Data of responsiveness are currently being obtained.

Entities:  

Mesh:

Year:  2001        PMID: 11424632     DOI: 10.1177/135245850100700208

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  42 in total

1.  MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.

Authors:  P Grossman; L Kappos; H Gensicke; M D'Souza; D C Mohr; I K Penner; C Steiner
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

Review 2.  Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice.

Authors:  Deborah M Miller; Rebecca Allen
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

3.  Quantitative T2' imaging in patients with clinically isolated syndrome.

Authors:  L Y Reitz; M Inglese; J Fiehler; J Finsterbusch; B Holst; C Heesen; R Martin; S Schippling
Journal:  Acta Neurol Scand       Date:  2012-01-03       Impact factor: 3.209

Review 4.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

5.  Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis.

Authors:  T Hayton; J Furby; K J Smith; D R Altmann; R Brenner; J Chataway; K Hunter; D J Tozer; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2011-08-24       Impact factor: 4.849

6.  Impact and characteristics of quality of life in Japanese patients with multiple sclerosis.

Authors:  Hiromi Kikuchi; Nobuhiro Mifune; Masaaki Niino; Sadayoshi Ohbu; Jun-ichi Kira; Tatsuo Kohriyama; Kohei Ota; Masami Tanaka; Hirofumi Ochi; Shunya Nakane; Masaji Maezawa; Seiji Kikuchi
Journal:  Qual Life Res       Date:  2010-08-11       Impact factor: 4.147

Review 7.  Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.

Authors:  Richard A Rudick; Deborah M Miller
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  An Exploratory Investigation of Social Stigma and Concealment in Patients with Multiple Sclerosis.

Authors:  Jonathan E Cook; Adriana L Germano; Gertraud Stadler
Journal:  Int J MS Care       Date:  2016 Mar-Apr

Review 9.  Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.

Authors:  Alexander Tallner; Klaus Pfeifer; Mathias Mäurer
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

10.  Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.

Authors:  Xavier Montalban; Giancarlo Comi; Jack Antel; Paul O'Connor; Ana de Vera; Malika Cremer; Nikolaos Sfikas; Philipp von Rosenstiel; Ludwig Kappos
Journal:  J Neurol       Date:  2015-09-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.